Skip to main content

Relay Therapeutics, Inc.

RLAY
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001812364

In the last 90 days, Relay Therapeutics, Inc. insiders filed 0 open-market purchases and 13 sales; 259 institutions reported holding it in 13F filings for Q2 2026, worth $4.58B in total; Duquesne Family Office is the only superinvestor holding it.

Q2 2021 vs. Q1 2021

How the institutions holding Relay Therapeutics, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of RLAY: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders137125−12
Shares85.6M89.1M+3.55M (+4.1%)
Value$2.96B$3.26B+$301.6M (+10.2%)

New holders (11)

Institutions that held Relay Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to RLAY in Q2 2021
InstitutionSharesValue% of portfolio
First Light Asset Management, LLC390,555$14.3M0.86%
Alpine Global Management, LLC135,465$4.96M0.68%
Jump Financial, LLC18,125$663.0K0.06%
Gotham Asset Management, LLC11,422$418.0K0.02%
Blueshift Asset Management, LLC8,120$297.0K0.02%
American Financial Group Inc7,484$274.0K0.07%
Winton Group Ltd6,183$226.0K0.01%
HighMark Wealth Management LLC2,396$88.0K0.06%
FORA Capital, LLC1,010$37.0K0.01%
Dark Forest Capital Management LP30$1.00K0.00%
Captrust Financial Advisors7$00.00%

Sold out (23)

Institutions that held Relay Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.